Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index; none of the 57 sources its claims cite is checked for support yet.

Clearance kinetics of the VGF-derived neuropeptide TLQP-21

Open access

Abstract

TLQP-21 is a multifunctional neuropeptide and a promising new medicinal target for cardiometabolic and neurological diseases. However, to date its clearance kinetics and plasma stability have not been studied. The presence of four arginine residues led us to hypothesize that its half-life is relatively short. Conversely, its biological activities led us to hypothesize that the peptide is still taken up by adipose tissues effectively. [125 I]TLQP-21 was i.v. administered in rats followed by chasing the plasma radioactivity and assessing tissue uptake. Plasma stability was measured using LC-MS. In vivo lipolysis was assessed by the palmitate rate of appearance. Results A small single i.v. dose of [125 I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, k t, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, k i, of 0.71/min. The total net uptake by adipose tissue accounts for 4.4% of the entire dose equivalent while the liver, pancreas and adrenal gland showed higher uptake. Uptake by the brain was negligible, suggesting that i.v.-injected peptide does not cross the blood-brain-barrier. TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo. Finally, TLQP-21 was rapidly degraded producing several N-terminal and central sequence fragments after 10 and 60 min in plasma in vitro. This study investigated the clearance and stability of TLQP-21 peptide for the first time. While its pro-lipolytic effect supports and extends previous findings, its short half-life and sequential cleavage in the plasma suggest strategies for chemical modifications in order to enhance its stability and therapeutic efficacy.

Overview

CoChat Summary

TL;DR

This study provides the first characterization of TLQP-21 clearance kinetics and plasma stability, showing a short initial half-life and rapid plasma degradation despite sustained pro-lipolytic activity in rats. The authors conclude that chemical modification may be needed to improve TLQP-21 stability and therapeutic efficacy.

Key findings

  • After i.v. bolus of [125I]TLQP-21 in rats, plasma clearance was exponential: corrected initial half-life was 0.97 min (ki′ = 0.71/min) and terminal half-life was 110 min (kt = 0.0063/min). The paper reports mean residence time 159 min, terminal volume of distribution 4258 ml/kg, total body clearance 27.1 ml/kg/min, and that 99% of injected peptide would be cleared in 6.4 min at the initial rate.
  • Total net uptake by adipose tissue accounted for 4.4% of the entire dose equivalent; liver, pancreas, and adrenal gland showed higher uptake, while brain uptake was negligible, suggesting i.v.-injected peptide does not cross the blood-brain barrier. Pancreas and kidney had the greatest uptake per tissue weight/protein; adipose tissue had the least per unit weight but was comparable per tissue protein; skeletal muscle was a major whole-organ site due to its mass. C3aR1 expression was highest in liver, adipose tissue, and heart, lower in brain, and negligible in skeletal muscle.
  • In 100% mouse plasma, full-length TLQP-21 was not identifiable after 10 min. At 10 min the most enriched fragment was TLQPPASSRRRHFHHALPPA, suggesting the C-terminal arginine is cleaved first; HFHHALPPAR indicated central arginines are also rapidly cleaved. At 60 min, only N-terminal hexa- and hepta-peptides and HFHHALPPA remained.
  • TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo: palmitate rate of appearance was 29% greater in the TLQP-21-treated group than in vehicle-treated controls, and plasma palmitate AUCs differed significantly between groups. Control plasma palmitate fell to ~75% of initial value, whereas it was sustained in the TLQP-21 group.

Methods

  • Two series of experiments used male Sprague Dawley rats on regular rodent chow (4.5% dietary fat), conducted in the morning without prior fasting. For clearance/tissue distribution, rats (n=8, ~400 g) received i.v. [125I]TLQP-21 (6–10 μCi, specific activity ~0.25 μCi/μg), with repeated blood collections at 5-min intervals for 20 min, followed by tissue collection.
  • For lipolysis, rats (n=8) received constant i.v. [U-13C]palmitate at 0.5 μmol·kg−1·min−1, then isoproterenol at 30 ng·min−1, followed by a bolus of 40 μg TLQP-21 or saline; blood was sampled for 60 min, and plasma palmitate concentration AUC and palmitate Ra were measured.
  • Plasma stability used TLQP-21 incubated in 100% mouse plasma at 1 mM at 37°C for 0, 10, 30, and 60 min, with LC-MS analysis. C3aR1 expression was measured by QPCR in selected organs. Statistics used mean±SEM, non-paired Student’s t-test, single-factor ANOVA with Tukey post hoc, and α=0.05.

Limitations

  • The paper states that tissue uptake is net uptake only; reversal/release was not measured, so gross uptake is assumed to be greater. It also states that significance of uptake by pancreas, kidney, and adrenals is premature to speculate, that the precise function of TLQP-21 in myocytes remains to be clarified, that the heart was not tested for ligand-receptor binding, and that whether the peptide alters FFA uptake remains to be determined.
  • The paper states that the hypothesis that larger or more frequent doses could prolong half-life needs validation in future investigations.
  • Evident from the text: experiments used only male Sprague Dawley rats (n=8 per protocol), without fasting, and plasma stability was tested in 100% mouse plasma in vitro at 1 mM rather than in rat or human plasma or at the low in vivo dose (<0.1 mg/kg), limiting direct translation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.npep.2018.06.003

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 31 Not checked · 69 Own results and interpretations

48 more claims

Create a free account to see all 100 claims and to verify the 49 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 19
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 45 references

Cited by

See all 21

Metadata

Authors
Guo, Z., Sahu, B. S., He, R., Finan, B., Cero, C., Verardi, R., Razzoli, M., Veglia, G., Di Marchi, R. D., Miles, J. M., & Bartolomucci, A.
Affiliations
  • Mayo Clinic (US)
  • University of Minnesota (US)
Corresponding author
Bartolomucci, Alessandro
Venue
Neuropeptides
Publisher
Elsevier BV
Published
2018-10
Volume
71
Pages
97-103
ISSN
0143-4179 (ISSN-L)
OpenAlex
W2809384620
Cited by
21
References
45
Citations by year
2025: 3 · 2024: 1 · 2023: 3 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 1
FWCI
1.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropeptides (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
NIH, and Decade of Discovery in Diabetes Grant, Minnesota Partnership for Biotechnology and Medical Genomic (R01DK102496, RO1 HL67933)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
Keywords
TLQP-21, plasma stability, peptide degradation, lipolysis, isoproterenol, blood-brain barrier, arginine-rich peptides, peptide modification, cardiometabolic disease, neurological disorders
MeSH terms
Animals, Lipolysis, Male, Metabolic Clearance Rate, Peptide Fragments, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clearance kinetics of the VGF-derived neuropeptide TLQP-21. https://app.cochat.ai/papers/10.1016/j.npep.2018.06.003
The paper
Guo, Z., Sahu, B. S., He, R., Finan, B., Cero, C., Verardi, R., Razzoli, M., Veglia, G., Di Marchi, R. D., Miles, J. M., & Bartolomucci, A. (2018). Clearance kinetics of the VGF-derived neuropeptide TLQP-21. Neuropeptides. https://doi.org/10.1016/j.npep.2018.06.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.